Table 4. Univariate and multivariate analyses of clinical factors for overall survival in a real-world cohort.
| Clinical factor | Patients (n) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95.0% CI) | P-value | HR (95.0% CI) | P-value | ||
| Sex | |||||
| M | 102 | 1.33 (0.81–2.20) | 0.26 | – | – |
| F | 157 | 1 | – | ||
| Smoking status | |||||
| Never smoked | 187 | 1 | – | ||
| Current or Ex-smoker | 72 | 1.52 (0.91–2.56) | 0.112 | – | – |
| ECOG PS | |||||
| 0–1 | 239 | 1 | – | ||
| 2–4 | 20 | 1.50 (0.68–3.31) | 0.313 | – | – |
| BMs | |||||
| Present | 82 | 2.03 (1.23–3.35) | 0.006* | 1.97 (1.19–3.26) | 0.008* |
| Absent | 177 | 1 | 1 | ||
| EGFR mutation status | |||||
| Group 1a | 207 | 0.58 (0.36–1.00) | 0.05 | 0.59 (0.34–1.02) | 0.06 |
| Group 2–3b, c | 52 | 1 | 1 | ||
| Tumor response to afatinib treatment | |||||
| PR | 180 | 0.43 (0.26–0.71) | 0.001* | 0.47 (0.28–0.77) | 0.003* |
| SD/PD | 79 | 1 | 1 | ||
| Afatinib dose during the first 6 months of treatment (mg) | |||||
| 40 | 139 | 0.997 (0.61–1.64) | 0.992 | – | – |
| < 40 | 120 | 1 | – | ||
*P < 0.05.
aClassical mutation(s).
bComplex mutation with classical mutation.
cRare mutation with or without complex mutation.
BM, brain metastasis; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; F, female; HR, hazard ratio; M, male; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease.